|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
33,620,000 |
Market
Cap: |
117.67(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.295 - $6.09 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aquestive Therapeutics is a pharmaceutical company. Co. is developing orally administered products to deliver various molecules using its proprietary technologies, PharmFilm®. Co.'s products within its central nervous system portfolio, focused on epilepsy, include: Sympazan®, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome; and Libervant, a buccally, or inside of the cheek, administered soluble film formulation of diazepam, used as an alternative to device-dependent rescue therapies, available to patients with refractory epilepsy, which are a rectal gel and nasal sprays.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
158,668 |
Total Buy Value |
$0 |
$0 |
$0 |
$151,571 |
Total People Bought |
0 |
0 |
0 |
4 |
Total Buy Transactions |
0 |
0 |
0 |
5 |
Total Shares Sold |
75,000 |
75,000 |
75,000 |
75,000 |
Total Sell Value |
$429,685 |
$429,685 |
$429,685 |
$429,685 |
Total People Sold |
1 |
1 |
1 |
1 |
Total Sell Transactions |
2 |
2 |
2 |
2 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2024-03-15 |
4 |
AS |
$6.00 |
$300,000 |
D/D |
(50,000) |
984,476 |
|
-42% |
|
Jung Cassie |
SVP, Operations |
|
2024-03-10 |
4 |
D |
$4.88 |
$5,524 |
D/D |
(1,132) |
237,754 |
|
- |
|
Wargacki Stephen |
SVP, Research & Development |
|
2024-03-10 |
4 |
D |
$4.88 |
$8,233 |
D/D |
(1,687) |
257,963 |
|
- |
|
Jung Cassie |
SVP, Operations |
|
2024-03-09 |
4 |
D |
$4.88 |
$40,504 |
D/D |
(8,300) |
238,886 |
|
- |
|
Boyd Peter E. |
See Remark |
|
2024-03-09 |
4 |
D |
$4.88 |
$40,846 |
D/D |
(8,370) |
237,628 |
|
- |
|
Barber Daniel |
President and CEO |
|
2024-03-09 |
4 |
D |
$4.88 |
$185,137 |
D/D |
(37,938) |
845,364 |
|
- |
|
Braender Lori J |
SVP, General Counsel |
|
2024-03-09 |
4 |
D |
$4.88 |
$51,386 |
D/D |
(10,530) |
313,231 |
|
- |
|
Wargacki Stephen |
SVP, Research & Development |
|
2024-03-09 |
4 |
D |
$4.88 |
$54,993 |
D/D |
(11,269) |
259,650 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2024-03-09 |
4 |
D |
$4.88 |
$28,768 |
D/D |
(5,895) |
1,034,476 |
|
- |
|
Toth A Ernest Jr |
SVP, Chief Financial Officer |
|
2024-03-09 |
4 |
D |
$4.88 |
$57,120 |
D/D |
(11,705) |
248,295 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2024-03-08 |
4 |
AS |
$5.19 |
$129,685 |
D/D |
(25,000) |
1,040,371 |
|
-28% |
|
Toth A Ernest Jr |
SVP, Chief Financial Officer |
|
2024-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
260,000 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2024-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
82,500 |
1,065,371 |
|
- |
|
Boyd Peter E. |
See Remark |
|
2024-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
86,250 |
245,998 |
|
- |
|
Wargacki Stephen |
SVP, Research & Development |
|
2024-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
112,500 |
270,919 |
|
- |
|
Kraus Carl N |
Chief Medical Officer |
|
2024-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
112,500 |
262,500 |
|
- |
|
Barber Daniel |
President and CEO |
|
2024-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
242,600 |
883,302 |
|
- |
|
Braender Lori J |
SVP, General Counsel |
|
2024-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
135,000 |
323,761 |
|
- |
|
Jung Cassie |
SVP, Operations |
|
2024-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
101,250 |
247,186 |
|
- |
|
Kraus Carl N |
Chief Medical Officer |
|
2023-08-09 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
|
- |
|
Wargacki Stephen |
SVP, Research & Development |
|
2023-03-10 |
4 |
D |
$0.79 |
$1,572 |
D/D |
(1,981) |
158,419 |
|
- |
|
Jung Cassie |
SVP, Operations |
|
2023-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,365) |
145,936 |
|
- |
|
Barber Daniel |
President and CEO |
|
2023-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
447,000 |
640,702 |
|
- |
|
Schobel Alexander Mark |
Chief Innovation/Tech Officer |
|
2023-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
982,871 |
|
- |
|
Jung Cassie |
SVP, Operations |
|
2023-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
110,000 |
146,747 |
|
- |
|
146 Records found
|
|
Page 1 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|